[CAR-T therapy for adult B-cell acute lymphoblastic leukemia].

Although adult B-cell acute lymphoblastic leukemia (B-ALL) responds to initial treatment, relapse and refractory cases are common. Even when these cases are treated with novel agents (blinatumomab, inotuzumab ozogamicin, etc.) and/or allogeneic stem cell transplantation, the prognosis remains poor. Recently, chimeric antigen receptor T-cell (CAR-T) therapy, targeting CD19, has demonstrated great potential in treating relapsed or refractory B-ALL. We have already used tisagenlecleucel in clinical practice, but it is limited to patients up to 25 years of age. This review summarizes the most recent evidence on CAR-T therapy for relapsed or refractory adult B-ALL, which has a poor prognosis when assessed in younger patients.